Agile Therapeutics Inc. Stock
Your prediction
Agile Therapeutics Inc. Stock
Our community identified positive and negative aspects for Agile Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Agile Therapeutics Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Agile Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agile Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agile Therapeutics Inc. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -0.770% | 1.801% | -17.320% | -57.946% | -36.580% | -71.740% | -95.128% |
| Evolus Inc | -1.110% | 4.046% | -22.078% | -56.098% | -33.945% | -51.351% | -67.857% |
| Sangamo Therapeutics Inc. | 8.620% | -15.717% | -37.386% | -65.319% | -36.993% | -83.471% | -97.618% |
Comments
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat